Lucid Diligence Brief: Insilico and Human Longevity collaboration
Lucid Diligence Brief: Insilico Medicine and Human Longevity collaborate on AI…
Lucid Diligence Brief: NeuroXT and BIDMC Expand Alzheimer’s AI Imaging Collaboration
Lucid Diligence Brief: NeuroXT and BIDMC expand their Alzheimer’s AI imaging…
Public Health Today—May 8, 2026
This weekly update in public health and biomedicine highlights emerging…
Lucid Diligence Brief: Lucent Diagnostics and Tempus AI Partnership
Lucid Diligence Brief: Lucent Diagnostics and Tempus AI Partnership…
Lucid Diligence Brief: Arrowhead ARO-PNPLA3 licensed to Madrigal
Lucid Diligence Brief: Arrowhead ARO-PNPLA3 licensed to Madrigal Professional…
Lucid Diligence Brief: Greywolf Therapeutics and Genomics strategic partnership
Lucid Diligence Brief: Greywolf Therapeutics and Genomics strategic……
Lucid Diligence Brief: Telix / Regeneron radiopharma collaboration
Lucid Diligence Brief: Telix / Regeneron radiopharma collaboration Professional…
Public Health Today—March 20, 2026
This weekly public health update highlights recent developments across clinical…
ESGO 2026 Preview: Key Gynaecological Oncology Highlights to Watch
ESGO 2026 at a Glance Get ready for ESGO 2026. LucidQuest’s preview brings…
ECCO 2026 Preview: Key Crohn’s and Colitis Highlights to Watch
ECCO 2026 at a Glance Get ready for ECCO 2026. LucidQuest’s preview brings…
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in immuno-fibrotic disease space
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in…
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics Professional…